• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Research Brief on 4-Fluoro-N-methyl-N-(piperidin-4-yl)benzenesulfonamide hydrochloride (CAS: 1353958-85-6)

4-Fluoro-N-methyl-N-(piperidin-4-yl)benzenesulfonamide hydrochloride (CAS: 1353958-85-6) is a chemical compound of significant interest in the field of chemical biology and medicinal chemistry. Recent studies have highlighted its potential as a key intermediate or active pharmaceutical ingredient (API) in the development of novel therapeutic agents. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, pharmacological properties, and potential applications in drug discovery.

The compound, characterized by its sulfonamide moiety and piperidine ring, has been investigated for its role in modulating various biological targets. Recent literature suggests its utility in the design of selective inhibitors for enzymes such as carbonic anhydrases and serotonin receptors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a scaffold for developing high-affinity ligands targeting G-protein-coupled receptors (GPCRs), which are critical in neurological and metabolic disorders.

In terms of synthesis, advancements have been made in optimizing the yield and purity of 4-Fluoro-N-methyl-N-(piperidin-4-yl)benzenesulfonamide hydrochloride. A novel catalytic method reported in Organic Process Research & Development (2024) utilizes palladium-catalyzed cross-coupling reactions to achieve a 90% yield, significantly reducing production costs and environmental impact. This methodological improvement is expected to facilitate its broader adoption in industrial-scale pharmaceutical manufacturing.

Pharmacokinetic studies have also shed light on the compound's metabolic stability and bioavailability. Preclinical trials indicate that it exhibits favorable absorption and distribution profiles, with low cytotoxicity in human cell lines. These properties make it a promising candidate for further development in oral drug formulations. However, challenges remain in addressing its moderate solubility in aqueous solutions, which may limit its efficacy in certain therapeutic contexts.

Emerging applications of 4-Fluoro-N-methyl-N-(piperidin-4-yl)benzenesulfonamide hydrochloride include its use in combination therapies for cancer and infectious diseases. A recent collaborative study between academic and industry researchers (2024) revealed its synergistic effects with existing chemotherapeutic agents, enhancing tumor suppression in murine models. Additionally, its antimicrobial properties are being explored, particularly against drug-resistant bacterial strains, as highlighted in a Nature Chemical Biology publication.

In conclusion, 4-Fluoro-N-methyl-N-(piperidin-4-yl)benzenesulfonamide hydrochloride represents a versatile and pharmacologically relevant compound with broad potential in drug discovery. Ongoing research is expected to further elucidate its mechanisms of action and expand its therapeutic applications. Future directions include structural optimization to improve solubility and the development of targeted delivery systems to enhance its clinical efficacy.

• 442124-75-6(1-(4-Fluorobenzenesulfonyl)piperidin-4-ylamine hydrochloride)
• 312-32-3(1-(4-Fluorophenylsulfonyl)piperidine)
• 1353971-21-7(4-Fluoro-N-methyl-N-(piperidin-3-yl)benzenesulfonamide hydrochloride)
• 1353985-93-9((1-((4-Fluorophenyl)sulfonyl)piperidin-3-yl)methanamine hydrochloride)
• 1044659-28-0(4-Fluoro-n-piperidin-4-yl-n-propyl-benzenesulfonamide)
• 349397-50-8(Benzenesulfonamide, N-cyclohexyl-N-ethyl-4-fluoro-)
• 1353958-87-8(1-((4-Fluorophenyl)sulfonyl)-N-methylpiperidin-4-amine hydrochloride)
• 1353972-68-5(1-((4-Fluorophenyl)sulfonyl)-N-methylpiperidin-3-amine hydrochloride)
• 913634-50-1(4-Fluoro-N-(piperidin-4-yl)benzenesulfonamide hydrochloride)
• 1185298-49-0((2-{1-(4-Fluorophenyl)sulfonylpiperidin-4-yl}ethyl)amine Hydrochloride)